Organogenesis (NASDAQ:ORGO) issued an update on its FY 2021 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $- for the period. The company issued revenue guidance of $438 million-454 million, compared to the consensus revenue estimate of $397.24 million.
Organogenesis stock traded up $0.06 during midday trading on Friday, reaching $14.98. The stock had a trading volume of 9,933 shares, compared to its average volume of 1,045,508. The firm has a fifty day moving average of $19.24. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of 41.45 and a beta of 1.84. Organogenesis has a twelve month low of $3.23 and a twelve month high of $24.34. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.10 and a current ratio of 2.50.
Organogenesis (NASDAQ:ORGO) last released its quarterly earnings results on Monday, May 10th. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.11. The business had revenue of $102.55 million for the quarter, compared to the consensus estimate of $86.30 million. Organogenesis had a net margin of 11.66% and a return on equity of 43.70%. As a group, research analysts predict that Organogenesis will post 0.33 EPS for the current fiscal year.
In related news, major shareholder Starr Wisdom sold 20,000 shares of Organogenesis stock in a transaction that occurred on Friday, April 9th. The shares were sold at an average price of $22.11, for a total transaction of $442,200.00. Following the sale, the insider now directly owns 386,297 shares in the company, valued at approximately $8,541,026.67. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Glenn H. Nussdorf sold 3,887,500 shares of Organogenesis stock in a transaction that occurred on Thursday, May 27th. The stock was sold at an average price of $16.40, for a total transaction of $63,755,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 4,212,112 shares of company stock worth $68,993,938. 57.20% of the stock is currently owned by corporate insiders.
Organogenesis Company Profile
Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic allograft wound covering and surgical barrier for application in the care of chronic and acute wounds or surgical implantation in spine, orthopedic, and sports medicine applications; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft, a dermal substitute for the treatment of DFUs; NuShield, a dehydrated placental tissue wound covering and surgical barrier applied to the target tissue to support native healing; and PuraPly Antimicrobial, an antimicrobial barrier skin substitute to treat chronic and acute wounds.
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.